Shinsei Yumoto

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Yuki Kitano · 5 shared papers, 2026 · strength 1.36
   • Paper The clinical utility of nutritional and immunological indices as prognostic factors in pancreatic cancer after pancreat… DOI 10.1016/j.pan.2026.04.008↗
   • Paper High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Can… DOI 10.1002/jhbp.70032↗
   • Paper Evaluation of Claudin 18.2 Expression Changes Following Chemotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.21873/anticanres.18442↗
2. Hiromitsu Hayashi · 5 shared papers, 2026 · strength 1.36
   • Paper The clinical utility of nutritional and immunological indices as prognostic factors in pancreatic cancer after pancreat… DOI 10.1016/j.pan.2026.04.008↗
   • Paper High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Can… DOI 10.1002/jhbp.70032↗
   • Paper Evaluation of Claudin 18.2 Expression Changes Following Chemotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.21873/anticanres.18442↗
3. Hirohisa Okabe · 5 shared papers, 2026 · strength 1.36
   • Paper The clinical utility of nutritional and immunological indices as prognostic factors in pancreatic cancer after pancreat… DOI 10.1016/j.pan.2026.04.008↗
   • Paper High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Can… DOI 10.1002/jhbp.70032↗
   • Paper Evaluation of Claudin 18.2 Expression Changes Following Chemotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.21873/anticanres.18442↗
4. Masaaki Iwatsuki · 5 shared papers, 2026 · strength 1.36
   • Paper The clinical utility of nutritional and immunological indices as prognostic factors in pancreatic cancer after pancreat… DOI 10.1016/j.pan.2026.04.008↗
   • Paper High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Can… DOI 10.1002/jhbp.70032↗
   • Paper Evaluation of Claudin 18.2 Expression Changes Following Chemotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.21873/anticanres.18442↗
5. Toru Takematsu · 2 shared papers, 2026 · strength 0.55
   • Paper High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Can… DOI 10.1002/jhbp.70032↗
   • Paper Neoadjuvant Chemotherapy Diminishes Ki-67 Overexpression and Persistent Overexpression Is a Poor Prognostic Factor in P… DOI 10.1097/mpa.0000000000002641↗
6. Yuki Adachi · 2 shared papers, 2026 · strength 0.53
   • Paper The clinical utility of nutritional and immunological indices as prognostic factors in pancreatic cancer after pancreat… DOI 10.1016/j.pan.2026.04.008↗
   • Paper A case of pancreatic cancer with high microsatellite instability exhibiting rare clinical features. DOI 10.1007/s12328-025-02256-2↗
7. Shigeki Nakagawa · 2 shared papers, 2026 · strength 0.51
   • Paper Neoadjuvant Chemotherapy Diminishes Ki-67 Overexpression and Persistent Overexpression Is a Poor Prognostic Factor in P… DOI 10.1097/mpa.0000000000002641↗
   • Paper A case of pancreatic cancer with high microsatellite instability exhibiting rare clinical features. DOI 10.1007/s12328-025-02256-2↗
8. Takashi Ofuchi · 1 shared paper, 2026 · strength 0.29
   • Paper The clinical utility of nutritional and immunological indices as prognostic factors in pancreatic cancer after pancreat… DOI 10.1016/j.pan.2026.04.008↗
9. Hiroki Tsubakihara · 1 shared paper, 2026 · strength 0.28
   • Paper Evaluation of Claudin 18.2 Expression Changes Following Chemotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.21873/anticanres.18442↗
10. Takashi Matsumoto · 1 shared paper, 2026 · strength 0.28
    • Paper High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Can… DOI 10.1002/jhbp.70032↗
11. Kosuke Mima · 1 shared paper, 2026 · strength 0.28
    • Paper High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Can… DOI 10.1002/jhbp.70032↗
12. Zhao Liu · 1 shared paper, 2026 · strength 0.28
    • Paper High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Can… DOI 10.1002/jhbp.70032↗
13. Takanobu Yamao · 1 shared paper, 2026 · strength 0.28
    • Paper Evaluation of Claudin 18.2 Expression Changes Following Chemotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.21873/anticanres.18442↗
14. Tatsunori Miyata · 1 shared paper, 2026 · strength 0.28
    • Paper Evaluation of Claudin 18.2 Expression Changes Following Chemotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.21873/anticanres.18442↗
15. Norio Uemura · 1 shared paper, 2026 · strength 0.27
    • Paper Neoadjuvant Chemotherapy Diminishes Ki-67 Overexpression and Persistent Overexpression Is a Poor Prognostic Factor in P… DOI 10.1097/mpa.0000000000002641↗
16. Rumi Itoyama · 1 shared paper, 2026 · strength 0.24
    • Paper A case of pancreatic cancer with high microsatellite instability exhibiting rare clinical features. DOI 10.1007/s12328-025-02256-2↗
17. Yukiko Suzuki · 1 shared paper, 2026 · strength 0.24
    • Paper A case of pancreatic cancer with high microsatellite instability exhibiting rare clinical features. DOI 10.1007/s12328-025-02256-2↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.